Table 3

Patient and transplant characteristics

PATIENT characteristicsTransplant characteristics
Immunosuppression
Patient #AgeEthnicityIndicationSingle versus doubleInduction agentCalcineurin inhibitor maintenanceAntimetabolite maintenanceSteroid maintenancemTOR inhibitor maintenance
176CaucasianCOPDDN/ATACNonePredN/A
273CaucasianIPFDBXBTACNonePredN/A
367CaucasianIPFRBXBCYCNonePredN/A
474CaucasianIPFLAMBTACMFMPredN/A
561CaucasianIPFRBXBTACNonePredN/A
674CaucasianCOPDDBXBTACNonePredN/A
760CaucasianCPFERAMBTACMFMPredN/A
863CaucasianCOPDLBXBTACMFMPredN/A
975CaucasianIPFLAMBTACMFMPredN/A
1075CaucasianCPFERBXBTACMFMPredN/A
1176CaucasianIPFLBXBTACMFMPredN/A
1261CaucasianILDLAMBTACMFMPredN/A
1373CaucasianCOPDLBXBTACAZAPredN/A
1480CaucasianCPFERAMBTACAZAPredN/A
1573CaucasianCPFE*LBXBTACMFMPredN/A
1682CaucasianIPFLBXBTACNonePredN/A
1761CaucasianCOPDLBXBTACNonePredN/A
1876CaucasianIPFRBXBTACMFMPredN/A
1970CaucasianCPFERAMBTACAZAPredN/A
2063CaucasianIPFRAMBTACMFMPredN/A
2176African-AmericanCOPDLBXBTACMFMPredN/A
2266CaucasianCOPDLBXBTACMFMPredN/A
2359CaucasianCOPDRAMBTACNonePredN/A
2458CaucasianIPFLBXBTACMFMPredN/A
  • *Features of bronchiectasis present with underlying CPFE.

  • AMB, alemtuzumab; AZA, azathioprine; BXB, basiliximab; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis with emphysema; CYC, ciclosporin; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MFM, mycophenolate mofetil; mTOR, mammalian target of rapamycin; Pred, prednisone; TAC, tacrolimus.